FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297229654> ?p ?o ?g. }

• W4297229654 endingPage "4508" @default.
• W4297229654 startingPage "4494" @default.
• W4297229654 abstract "Abstract Purpose: To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)–resistant triple-negative breast cancer (TNBC) and ER+HER2– breast cancer disease. Experimental Design: Following pathology review, 153 patients were identified as having residual cancer burden (RCB) II/III disease (TNBC n = 80; ER+HER2–n = 73). Baseline pre-NAC samples were available for evaluation for 32 of 80 TNBC and 36 of 73 ER+HER2– cases. Bright-field hematoxylin and eosin assessment allowed for tumor-infiltrating lymphocyte (TIL) evaluation in all cases. Multiplexed immunofluorescence was used to identify the abundance and distribution of immune cell subsets. Levels of checkpoints including PD-1/PD-L1 expression were also quantified. Findings were then validated using expression profiling of cancer and immune-related genes. Cytometry by time-of-flight characterized the dynamic changes in circulating immune cells with NAC. Results: RCB II/III TNBC and ER+HER2– breast cancer were immunologically “cold” at baseline and end of NAC. Although the distribution of immune cell subsets across subtypes was similar, the mRNA expression profiles were both subtype- and chemotherapy-specific. TNBC RCB II/III disease was enriched with genes related to neutrophil degranulation, and displayed strong interplay across immune and cancer pathways. We observed similarities in the dynamic changes in B-cell biology following NAC irrespective of subtype. However, NAC induced changes in the local and circulating tumor immune microenvironment (TIME) that varied by subtype and response. Specifically, in TNBC residual disease, we observed downregulation of stimulatory (CD40/OX40L) and inhibitory (PD-L1/PD-1) receptor expression and an increase in NK cell populations (especially non-cytolytic, exhausted CD56dimCD16–) within both the local TIME and peripheral white cell populations. Conclusions: This study identifies several potential immunologic pathways in residual disease, which may be targeted to benefit high-risk patients." @default.
• W4297229654 created "2022-09-28" @default.
• W4297229654 creator A5001737873 @default.
• W4297229654 creator A5014364684 @default.
• W4297229654 creator A5016015665 @default.
• W4297229654 creator A5019349196 @default.
• W4297229654 creator A5020035024 @default.
• W4297229654 creator A5020517461 @default.
• W4297229654 creator A5030536919 @default.
• W4297229654 creator A5034034892 @default.
• W4297229654 creator A5037039728 @default.
• W4297229654 creator A5038968301 @default.
• W4297229654 creator A5048086477 @default.
• W4297229654 creator A5049720751 @default.
• W4297229654 creator A5052903538 @default.
• W4297229654 creator A5055450638 @default.
• W4297229654 creator A5056715948 @default.
• W4297229654 creator A5067431043 @default.
• W4297229654 creator A5069116024 @default.
• W4297229654 creator A5076006564 @default.
• W4297229654 creator A5076395478 @default.
• W4297229654 creator A5083195897 @default.
• W4297229654 creator A5084722080 @default.
• W4297229654 creator A5084993667 @default.
• W4297229654 creator A5087121536 @default.
• W4297229654 date "2022-09-26" @default.
• W4297229654 modified "2023-10-14" @default.
• W4297229654 title "Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy–Resistant Early Breast Cancers" @default.
• W4297229654 cites W1486665165 @default.
• W4297229654 cites W1966128754 @default.
• W4297229654 cites W2002157461 @default.
• W4297229654 cites W2004630197 @default.
• W4297229654 cites W2024626836 @default.
• W4297229654 cites W2028433016 @default.
• W4297229654 cites W2032485712 @default.
• W4297229654 cites W2037027640 @default.
• W4297229654 cites W2047902191 @default.
• W4297229654 cites W2055749744 @default.
• W4297229654 cites W2096145980 @default.
• W4297229654 cites W2098150432 @default.
• W4297229654 cites W2098683355 @default.
• W4297229654 cites W2099175643 @default.
• W4297229654 cites W2100115138 @default.
• W4297229654 cites W2100357356 @default.
• W4297229654 cites W2106511557 @default.
• W4297229654 cites W2112434826 @default.
• W4297229654 cites W2120431466 @default.
• W4297229654 cites W2134878729 @default.
• W4297229654 cites W2135061646 @default.
• W4297229654 cites W2143451223 @default.
• W4297229654 cites W2146512944 @default.
• W4297229654 cites W2149668671 @default.
• W4297229654 cites W2150756255 @default.
• W4297229654 cites W2157058802 @default.
• W4297229654 cites W2161382947 @default.
• W4297229654 cites W2163871197 @default.
• W4297229654 cites W2165360012 @default.
• W4297229654 cites W2169914436 @default.
• W4297229654 cites W2299181842 @default.
• W4297229654 cites W2407664560 @default.
• W4297229654 cites W2560367415 @default.
• W4297229654 cites W2593437788 @default.
• W4297229654 cites W2594836176 @default.
• W4297229654 cites W2618433578 @default.
• W4297229654 cites W2762153201 @default.
• W4297229654 cites W2765484031 @default.
• W4297229654 cites W2771978163 @default.
• W4297229654 cites W2774267942 @default.
• W4297229654 cites W2907566829 @default.
• W4297229654 cites W2913289941 @default.
• W4297229654 cites W2949315168 @default.
• W4297229654 cites W2952406594 @default.
• W4297229654 cites W2980303761 @default.
• W4297229654 cites W2997794888 @default.
• W4297229654 cites W3005411249 @default.
• W4297229654 cites W3006930853 @default.
• W4297229654 cites W3007632958 @default.
• W4297229654 cites W3037713110 @default.
• W4297229654 cites W3081199965 @default.
• W4297229654 cites W3087157621 @default.
• W4297229654 cites W3091425478 @default.
• W4297229654 cites W3122868549 @default.
• W4297229654 cites W3130781357 @default.
• W4297229654 cites W3183916035 @default.
• W4297229654 cites W4240098044 @default.
• W4297229654 cites W788288083 @default.
• W4297229654 doi "https://doi.org/10.1158/1078-0432.ccr-22-0543" @default.
• W4297229654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36161312" @default.
• W4297229654 hasPublicationYear "2022" @default.
• W4297229654 type Work @default.
• W4297229654 citedByCount "3" @default.
• W4297229654 countsByYear W42972296542023 @default.
• W4297229654 crossrefType "journal-article" @default.
• W4297229654 hasAuthorship W4297229654A5001737873 @default.
• W4297229654 hasAuthorship W4297229654A5014364684 @default.
• W4297229654 hasAuthorship W4297229654A5016015665 @default.
• W4297229654 hasAuthorship W4297229654A5019349196 @default.
• W4297229654 hasAuthorship W4297229654A5020035024 @default.

• next